Enovis (NYSE:ENOV) Stock Price Down 9.3% – Time to Sell?

Shares of Enovis Corporation (NYSE:ENOV) fell 9.3% during mid-day trading on Thursday . The company traded as low as $26.48 and last traded at $27.3720. 74,306 shares were traded during trading, a decline of 93% from the average session volume of 1,078,881 shares. The stock had previously closed at $30.18.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Analyst Ratings Changes

Several brokerages recently weighed in on ENOV. Wells Fargo & Company dropped their target price on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research note on Friday. UBS Group reissued a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. William Blair started coverage on Enovis in a research note on Friday, April 17th. They set an “outperform” rating on the stock. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Enovis Stock Performance

The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. The firm has a 50-day moving average of $24.62 and a 200-day moving average of $23.97. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -1.39 and a beta of 1.34.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts predict that Enovis Corporation will post 3.12 earnings per share for the current year.

Insider Activity

In other news, insider Oliver Engert bought 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought 4,200 shares of company stock valued at $92,084 in the last three months. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Institutional investors have recently bought and sold shares of the business. Arax Advisory Partners purchased a new stake in shares of Enovis in the 4th quarter valued at $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Danske Bank A S purchased a new position in shares of Enovis during the third quarter worth $64,000. iSAM Funds UK Ltd acquired a new position in Enovis during the third quarter valued at $80,000. Finally, Brown Brothers Harriman & Co. acquired a new position in Enovis during the third quarter valued at $90,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.